Skip to main content
. 2016 Dec 31;8(5):8657–8669. doi: 10.18632/oncotarget.14395

Figure 2. Patients with male gender, KPS≤80 points, LDH≤216.

Figure 2

5U/L, extensive disease and metastatic sites<2 can benefit more from the management of etoposide and platinum-based chemotherapy (p<0.05 on uni- and multivariate analysis). MST, median survival time.